Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia

1. Bexobrutideg shows 80.9% response rate in CLL patients. 2. Phase I trial involved 48 patients, mean age 68.5. 3. No dose-limiting toxicities were noted. 4. Most common adverse events: purpura and fatigue. 5. Bexobrutideg degrades BTK via ubiquitination. 6. Key finding: sustained responses over time, with some patients achieving complete response. 7. Presented by Dr. Nirav N. Shah at 2025 SOHO Annual Meeting.